Karyopharm Therapeutics | KPTI - Pre Tax Profit


Karyopharm Therapeutics reported $-22.39M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 7.61B 2.04B Jun/2026
Abbott USD 2.39B 27M Mar/2026
Amgen USD 2.08B 570M Mar/2026
AstraZeneca USD 4.81B 894M Jun/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Bristol-Myers Squibb USD 4.99B 1.75B Jun/2026
Eli Lilly USD 8.85B 583.8M Mar/2026
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
GlaxoSmithKline GBP 2.68B 532M Jun/2026
Incyte USD 751.51M 407.91M Jun/2026
J&J USD 7.67B 988M Sep/2026
Karyopharm Therapeutics USD -22.39M 17.51M Mar/2026
MacroGenics USD -36.77M 21.84M Mar/2026
Merck USD -3.53B 6.95B Mar/2026
Nektar Therapeutics USD -43.09M 8.39M Mar/2026
Novartis USD 4.27B 430M Jun/2026
Novartis USD 3.84B 1.33B Mar/2026
Pfizer USD -653M 5.84B Jun/2026
Regeneron Pharmaceuticals USD 1.53B 696.6M Jun/2026
Roche Holding CHF 11.17B 6.38B Jun/2026
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Takeda JPY 162.72B 215.2B Jun/2026
Tectonic Therapeutic USD -18.97M 63K Dec/2025
TG Therapeutics USD 10.23M 10.13M Jun/2026
Ultragenyx Pharmaceutical USD -91M 93M Jun/2026
Xencor USD -21.92M 106.72M Jun/2026